Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
Leanne M WardFrancis H GlorieuxMichael P WhyteCraig F MunnsAnthony A PortaleWolfgang HöglerJill H SimmonsGary S GottesmanRaja PadidelaNoriyuki NambaHae Il CheongOla NilssonMeng MaoAngel ChenAlison SkrinarMary Scott RobertsErik Allen ImelPublished in: The Journal of clinical endocrinology and metabolism (2022)
Burosumab appears to improve outcomes both in younger and older children with XLH, including rickets, lower limb deformities, growth, and ALP, compared with Pi/D.